# US 2020/0368181 A1 · Methods of treating anti-nmdar-associated neuropsychiatric disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368181 A1
- Document ID: US20200368181A1
- Status: Published application
- Kind: A1
- Application number: 16/970,654
- Filed: 2019-02-19
- Published: 2020-11-26
- Earliest claimed: 2018-02-19
- Assignees: Vanderbilt University
- Applicants: Vanderbilt University
- Inventors: Jill M. Pulley
- Web page: https://patentgrep.com/patent/US20200368181A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 37/02: Immunomodulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.

## Claims

### Claim 1

A method of treating a neuropsychiatric disorder in a subject comprising administering a therapeutically effective amount of memantine, or a pharmaceutically acceptable salt thereof, to the subject, wherein the subject has a mutation in the ionotropic glutamate receptor NMDA type subunit 2A (GRIN2A) gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering to the subject is after the mutation in the ionotropic glutamate receptor NMDA type subunit 2A (GRIN2A) gene is detected in the subject.

### Claim 3 (depends on 2)

The method of claim 2, further comprising obtaining a sample from the subject and detecting the mutation in the ionotropic glutamate receptor NMDA type subunit 2A (GRIN2A) gene in the sample.

### Claim 4 (depends on 1, 2, 3)

The method of any of claims 1-3, wherein the mutation results in a T141M amino acid substitution in the ionotropic glutamate receptor, NMDA 2A (GluN2A).

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1-4, wherein the subject expresses autoantibodies to the ionotropic glutamate receptor, NMDA 2A (GluN2A) and/or anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMDA receptor.

### Claim 6

A method of treating a neuropsychiatric disorder in a subject comprising administering a therapeutically effective amount of memantine, or a pharmaceutically acceptable salt thereof, to the subject, wherein the subject expresses autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) and/or anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMDA receptor.

### Claim 7

A method of treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of memantine or a pharmaceutically acceptable salt thereof.

### Claim 8

A method of treating a neuropsychiatric disorder in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of memantine or a pharmaceutically acceptable salt thereof after autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) and/or anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMDA receptor are detected in the subject.

### Claim 9 (depends on 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 2-8, further comprising obtaining a sample from the subject and detecting autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) in the sample.

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 2-9, further comprising obtaining a sample from the subject and detecting anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMDA receptor in the sample.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the neuropsychiatric disorder is neuropsychiatric systemic lupus erythematosus (NPSLE), systemic lupus erythematosus (SLE) with neurological manifestations, anti-NMDAR encephalitis, anti-NMDAR movement disorders, Sjögren's Syndrome (SS) with neurological manifestations, schizophrenia, Creutzfeldt-Jakob disease, myoclonic atonic epilepsy, postural orthostatic tachycardia syndrome (POTS), or Alzheimer's disease.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the neuropsychiatric disorder is neuropsychiatric systemic lupus erythematosus (NPSLE) or systemic lupus erythematosus (SLE) with neurological manifestations.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the subject exhibits one or more of the following symptoms: seizures, psychosis, epilepsy, a cerebrovascular event, lesion of cranial nerves, motor disturbances, quantitative alterations of consciousness, cognitive dysfunction, headache, peripheral neuropathy, and/or fatigue.

### Claim 14 (depends on 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 6-13 wherein the subject has a mutation in the ionotropic glutamate receptor NMDA type subunit 2A (GRIN2A) gene.

### Claim 15 (depends on 14)

The method of claim 14, wherein the mutation results in a T141M amino acid substitution in the ionotropic glutamate receptor, NMDA 2A (GluN2A).

### Claim 16 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 6-15, wherein the autoantibodies are antibodies to the NR2A subunit(s) DWDYS (residues 283-287) and/or DWEYS of NMDAR determined by ELISA.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 1-16, wherein the pharmaceutically acceptable salt of memantine is memantine hydrochloride.
